Other potential mechanisms include the anti-inflammatory properties of antidepressants (51,52) with sigma-1 receptor agonist effect (32,45,53) and/or decreasing acid sphingomyelinase activity (29,48), which may have an important value in regulating inflammation by inhibiting cytokine production in COVID-19, reduction in platelet aggregation, decreased mast cell degranulation, interference with endolysosomal viral trafficking, and increased melatonin levels (27,45). This evidence concerns the gene SMPD1 and COVID-19.